Table 4

SF-36 and EQ-5D measures over time and effect sizes of BoNT/A treatment within the HRQL dimensions assessed in 50 patients with focal dystonia

Cranial dystoniaCervical dystonia
BaselineFirst
follow up
Second
follow up
BoNT/A
effect size
BaselineFirst follow upSecond
follow up
BoNT/A
effect size
SF-36:
 PF63.6  (26.0)70.8  (27.9)4-150 59.6  (29.6)0.3  (0.6)73.8  (22.7)74.6  (27.5)74.2  (23.1)0.03  (0.9)
 SF67.9 (27.5)77.4 (25.3)4-160 68.4 (29.1)0.4 (0.7)74.4 (20.6)83.0 (19.6)4-160 70.9 (24.1)0.4 (0.6)
 RP53.0 (34.1)63.0 (37.6)4-150 49.0 (37.8)0.3 (0.6)52.0 (31.4)64.0 (35.4)4-150 46.0 (29.5)0.4 (0.7)
 RE61.2 (41.6)75.8 (34.1)4-150 59.8 (40.8)0.4 (0.8)75.9 (39.2)78.5 (33.3)73.2 (37.3)0.1 (0.4)
 MH62.2 (16.9)70.9 (21.0)4-160 66.4 (18.9)0.5 (0.7)62.7 (19.0)74.6 (14.4)4-160 59.0 (21.6)0.7 (1.0)
 VIT54.8 (22.0)63.2 (24.6)4-150 53.6 (24.3)0.4 (0.7)55.6 (22.4)64.8 (23.0)4-160 55.0 (23.8)0.4 (0.7)
 BP60.5 (24.3)64.2 (27.8)60.8 (27.6)0.2 (0.6)4-151 55.7 (25.0)74.2 (20.5)4-160 57.5 (26.5)0.8 (0.9)4-151
 GH47.8 (18.1)51.3 (19.6)48.3 (19.8)0.2 (0.7)53.2 (19.6)52.3 (18.1)49.0 (18.5)−0.1 (0.7)
EQ-5D:
 UI0.59 (0.26)0.66 (0.29)0.63 (0.27)0.3 (0.9)0.60 (0.24)0.76 (0.21)4-160 0.66 (0.21)0.6 (0.9)
 VAS59.6 (19.9)67.4 (21.4)4-150 62.2 (20.3)0.4 (0.9)57.0 (21.2)69.2 (18.0)4-150 58.8 (15.9)0.6 (1.1)
  • 4-150 p<0.05;

  • 4-160 p<0.01 for difference of first follow up assessment compared with baseline (paired ttest); no significant differences between second follow up and baseline assessments;

  • 4-151 p<0.01 for difference in BoNT/A effect size between cranial and cervical dystonia (unpaired ttest); BoNT/A effect size=(first follow up score–baseline score)/1 SD of baseline scores; PF=physical functioning; SF=social functioning; RP=role-physical; RE=role-emotional; MH=mental health; VIT=vitality; BP=bodily pain; GH=general health; UI=utility index; VAS=visual analogue scale.